IPO13

Across TCGA pan-cancer cohorts, IPO13 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of IPO13’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where IPO13 RNA is repressed in tumor relative to normal tissue. In most cancer types IPO13 is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

KIRC, HNSC, and LIHC are the cancer types where IPO13 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IPO13 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.980	<.001	11	view →
HNSC	Female	II,III,IV	+0.691	<.001	10	view →
LIHC	Female	II,III,IV	+1.536	<.001	9	view →
LUSC	Female	All	+1.150	<.001	8	view →
KIRP	Male	All	−0.700	<.001	8	view →
BRCA	All	All	+0.329	<.001	8	view →
KICH	All	All	−0.549	<.001	7	view →
CHOL	Male	All	+1.810	<.001	5	view →
BLCA	Female	All	+0.586	.011	5	view →
STAD	Male	II,III,IV	+0.622	.011	4	view →
LUAD	All	All	+0.223	.003	4	view →
THCA	Male	III,IV	−0.459	.040	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

IPO13–KIRC

Open the KIRC breakdown →